Evolution of the human immunodeficiency virus type 1 protease: Effects on viral replication capacity and protease robustness

Journal of General Virology

Volumn 93, Issue PART 12, 2012, Pages 2625-2634

  Capel, Elena ^a   Martrus, Glória ^a   Parera, Mariona ^a   Clotet, Bonaventura ^a   Martínez, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RECOMBINANT ENZYME;

AMINO ACID SEQUENCE; ARTICLE; CLONE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MUTAGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE; CONSERVED SEQUENCE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENETIC VARIATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; REASSORTANT VIRUSES; SEQUENCE HOMOLOGY, AMINO ACID; TIME FACTORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869228836     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.045492-0     Document Type: Article

References (49)

1. Alizon, S., von Wyl, V., Stadler, T., Kouyos, R. D., Yerly, S., Hirschel, B., Böni, J., Shah, C., Klimkait, T. & other authors (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 6, e1001123.
2. Ariën, K. K., Troyer, R. M., Gali, Y., Colebunders, R. L., Arts, E. J. & Vanham, G. (2005). Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS 19, 1555-1564.
3. Ariën, K. K., Vanham, G. & Arts, E. J. (2007). Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol 5, 141-151.
4. Betancor, G., Puertas, M. C., Nevot, M., Garriga, C., Martínez, M. A., Martinez-Picado, J. & Menéndez-Arias, L. (2010). Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure. Antimicrob Agents Chemother 54, 4799-4811.
5. Chopera, D. R., Mlotshwa, M., Woodman, Z., Mlisana, K., de Assis Rosa, D., Martin, D. P., Abdool Karim, S., Gray, C. M., Williamson, C. & CAPRISA 002 Study Team (2011). Virological and immunological factors associated with HIV-1 differential disease progression in HLAB 58:01-positive individuals. J Virol 85, 7070-7080.
6. Derdeyn, C. A., Decker, J. M., Bibollet-Ruche, F., Mokili, J. L., Muldoon, M., Denham, S. A., Heil, M. L., Kasolo, F., Musonda, R. & other authors (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019-2022.
7. Dorrucci, M., Phillips, A. N., Longo, B., Rezza, G. & Italian Seroconversion Study (2005). Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. AIDS 19, 331-335.
8. Dorrucci, M., Rezza, G., Porter, K., Phillips, A. & Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration (2007). Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 195, 525-534.
9. Draghi, J. A., Parsons, T. L., Wagner, G. P. & Plotkin, J. B. (2010). Mutational robustness can facilitate adaptation. Nature 463, 353-355.
10. Fernandez, G., Clotet, B. & Martínez, M. A. (2007). Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol 81, 2485-2496.
11. Gali, Y., Berkhout, B., Vanham, G., Bakker, M., Back, N. K. & Ariën, K. K. (2007). Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology 364, 140-146.
12. Hemelaar, J. (2012). The origin and diversity of the HIV-1 pandemic. Trends Mol Med 18, 182-192.
13. Herbeck, J. T., Gottlieb, G. S., Li, X., Hu, Z., Detels, R., Phair, J., Rinaldo, C., Jacobson, L. P., Margolick, J. B. & Mullins, J. I. (2008). Lack of evidence for changing virulence of HIV-1 in North America. PLoS ONE 3, e1525.
14. Herbeck, J. T., Müller, V., Maust, B. S., Ledergerber, B., Torti, C., Di Giambenedetto, S., Gras, L., Günthard, H. F., Jacobson, L. P. & other authors (2012). Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS 26, 193-205.
15. Ibáñez, A., Clotet, B. & Martínez, M. A. (2000). Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J Gen Virol 81, 85-95.
16. Kawashima, Y., Pfafferott, K., Frater, J., Matthews, P., Payne, R., Addo, M., Gatanaga, H., Fujiwara, M., Hachiya, A. & other authors (2009). Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458, 641-645.
17. Kearney, M., Maldarelli, F., Shao, W., Margolick, J. B., Daar, E. S., Mellors, J. W., Rao, V., Coffin, J. M. & Palmer, S. (2009). Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 83, 2715-2727.
18. Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S. & other authors (2008). Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105, 7552-7557.
19. Kisic, M., Matamoros, T., Nevot, M., Mendieta, J., Martinez-Picado, J., Martínez, M. A. & Menéndez-Arias, L. (2011). Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase. J Biol Chem 286, 20615-20624.
20. Korber, B., Muldoon, M., Theiler, J., Gao, F., Gupta, R., Lapedes, A., Hahn, B. H., Wolinsky, S. & Bhattacharya, T. (2000). Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796.
21. Kosakovsky Pond, S. L. & Frost, S. D. (2005). Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 22, 1208-1222.
22. Leslie, A. J., Pfafferott, K. J., Chetty, P., Draenert, R., Addo, M. M., Feeney, M., Tang, Y., Holmes, E. C., Allen, T. & other authors (2004). HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10, 282-289.
23. Loeb, D. D., Swanstrom, R., Everitt, L., Manchester, M., Stamper, S. E. & Hutchison, C. A., III (1989). Complete mutagenesis of the HIV-1 protease. Nature 340, 397-400.
24. Martinez-Picado, J. & Martínez, M. A. (2008). HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res 134, 104-123.
25. Martinez-Picado, J., Savara, A. V., Sutton, L. & D'Aquila, R. T. (1999). Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73, 3744-3752.
26. Más, A., López-Galíndez, C., Cacho, I., Gómez, J. & Martínez, M. A. (2010). Unfinished stories on viral quasispecies and Darwinian views of evolution. J Mol Biol 397, 865-877.
27. Maschera, B., Furfine, E. & Blair, E. D. (1995). Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 69, 5431-5436.
28. Miura, T., Brockman, M. A., Brumme, Z. L., Brumme, C. J., Pereyra, F., Trocha, A., Block, B. L., Schneidewind, A., Allen, T. M. & other authors (2009). HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 83, 140-149.
29. Muller, H. J. (1964). The relation of recombination to mutational advance. Mutat Res 106, 2-9.
30. Müller, V., Ledergerber, B., Perrin, L., Klimkait, T., Furrer, H., Telenti, A., Bernasconi, E., Vernazza, P., Gü nthard, H. F., Bonhoeffer, S. & Swiss HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS 20, 889-894.
31. Nevot, M., Martrus, G., Clotet, B. & Martínez, M. A. (2011). RNA interference as a tool for exploring HIV-1 robustness. J Mol Biol 413, 84-96.
32. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S. & Boucher, C. A. (1999). Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13, 2349-2359.
33. Parera, M., Ibañez, A., Clotet, B. & Martinez, M. A. (2004). Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. J Infect Dis 189, 1444-1451.
34. Parera, M., Fernandez, G., Clotet, B. & Martínez, M. A. (2007). HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol 24, 382-387.
35. Rolland, M., Brander, C., Nickle, D. C., Herbeck, J. T., Gottlieb, G. S., Campbell, M. S., Maust, B. S. & Mullins, J. I. (2007). HIV-1 over time: fitness loss or robustness gain? Nat Rev Microbiol 5, 1-2.
36. Sharp, P. M. & Hahn, B. H. (2011). Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1, a006841.
37. Sinicco, A., Fora, R., Raiteri, R., Sciandra, M., Bechis, G., Calvo, M. M. & Gioannini, P. (1997). Is the clinical course of HIV-1 changing? Cohort study. BMJ 314, 1232-1237.
38. Stoddart, C. A., Liegler, T. J., Mammano, F., Linquist-Stepps, V. D., Hayden, M. S., Deeks, S. G., Grant, R. M., Clavel, F. & McCune, J. M. (2001). Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 7, 712-718.
39. Tamura, K., Dudley, J., Nei, M. & Kumar, S. (2007). MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24, 1596-1599.
40. Troude, P., Chaix, M. L., Tran, L., Deveau, C., Seng, R., Delfraissy, J. F., Rouzioux, C., Goujard, C., Meyer, L. & ANRS Primo cohort (2009). No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 23, 1261-1267.
41. Troyer, R.M., McNevin, J., Liu, Y., Zhang, S. C., Krizan, R.W., Abraha, A., Tebit, D. M., Zhao, H., Avila, S. & other authors (2009). Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 5, e1000365.
42. van Manen, D., Gras, L., Boeser-Nunnink, B. D., van Sighem, A. I., Maurer, I., Mangas Ruiz, M. M., Harskamp, A. M., Steingrover, R., Prins, J. M. & other authors (2011). Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control. AIDS 25, 2217-2226.
43. van Nimwegen, E. (2006). Epidemiology. Influenza escapes immunity along neutral networks. Science 314, 1884-1886.
44. + T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. J Infect Dis 180, 1803-1808.
45. Vermund, S. H. & Leigh-Brown, A. J. (2012). The HIV Epidemic: high-income countries. Cold Spring Harb Perspect Med 2, a007195.
46. Walker, B. & McMichael, A. (2012). The T-cell response to HIV. Cold Spring Harb Perspect Med (in press). doi:10.1101/cshperspect.a007054
47. Wild, G., Gardner, A. & West, S. A. (2009). Adaptation and the evolution of parasite virulence in a connected world. Nature 459, 983-986.
48. Yuste, E., Sánchez-Palomino, S., Casado, C., Domingo, E. & Ló pez-Galíndez, C. (1999). Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 73, 2745-2751.
49. Yuste, E., Ló pez-Galíndez, C. & Domingo, E. (2000). Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol 74, 9546-9552.